title: Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Caocci
authors.forename: Adriana
authors.initials: A
authors.lastname: Vacca
authors.forename: Antonio
authors.initials: A
authors.lastname: Ledda
authors.forename: Francesca
authors.initials: F
authors.lastname: Murgia
authors.forename: Eugenia
authors.initials: E
authors.lastname: Piras
authors.forename: Marianna
authors.initials: M
authors.lastname: Greco
authors.forename: Marcella
authors.initials: M
authors.lastname: Arras
authors.forename: Sandra
authors.initials: S
authors.lastname: Atzeni
authors.forename: Roberto
authors.initials: R
authors.lastname: Littera
authors.forename: Giorgio
authors.initials: G
authors.lastname: La Nasa
mesh_terms: D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D000069439:Dasatinib; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D055502:Secondary Prevention; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib